Skip to main content
OpenTrials
Completed

NCT Number: NCT01558323

Pharmacokinetics of LCQ908 in Patients With Renal Impairment

This study will compare the pharmacokinetics of LCQ908 in subjects with varying degrees of renal impairment to healthy subjects

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Novartis Investigative Site, Orlando, Florida, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Individuals with renal impairment only
  • Estimated Creatinine Clearance (CLcr) by the Cockroft-Gault equation ≤80mL/min;
  • Mild renal impairment defined as CLcr 50-80 mL/min
  • Moderate renal impairment defined as CLcr 30-50 mL/min
  • Severe renal impairment defined as CLcr <30 mL/min
  • Healthy subjects only • Estimated CLcr by the Cockroft-Gault equation >80mL/min

Exclusion criteria

  • All Individuals
  • A past medical history of clinically significant ECG abnormalities or a family history of a prolonged QT-interval syndrome.
  • Female subjects must be of non child bearing potential or use an effective method of contraception.
  • Individuals with renal impairment
  • Renal transplant at any time.
  • Subjects undergoing any method of dialysis (hemodialysis, peritoneal dialysis) within the last 3 months.
  • History of clinically significant chronic or recurrent urinary tract infection active and requiring antibiotic treatment within the past 30 days.
  • Any medication that is contraindicated in moderate or severe renally impaired population
  • Healthy subjects
  • History or presence of impaired renal function as indicated by clinically significantly abnormal creatinine or BUN and/or urea values, or abnormal urinary constituents (e.g., albuminuria)
  • Evidence of urinary obstruction or difficulty in voiding at screening
  • History or presence of hepatitis B or C and/or positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result at screening.

Other protocol-defined inclusion/exclusion criteria may apply.

Treatment and study plan

LCQ908

Drug

Participants will receive a single oral dose of LCQ908

Primary outcomes

  1. Area under the plasma concentration-time profile from time zero to the time of the last quantifiable concentration (AUClast) of LCQ908

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

  2. Area under the plasma concentration-time profile from time zero extrapolated to infinite time [AUC(0-inf)] of LCQ908

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

  3. Maximum plasma concentration (Cmax) of LCQ908

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

Secondary outcomes

  1. Number of participants with adverse events (AEs), serious adverse events (SAEs) and death

    Time frame: Day 29

    AEs are defined as any unfavorable and unintended diagnosis, symptom, sign (including an abnormal laboratory finding), syndrome or disease which either occurs during study, having been absent at baseline, or, if present at baseline, appears to worsen. SAEs are any untoward medical occurrences that result in death, are life threatening, require (or prolong) hospitalization, cause persistent or significant disability/incapacity, result in congenital abnormalities or birth defects, or are other conditions which in the judgment of investigators represent significant hazards.

  2. The apparent systemic clearance (CL/F) of LCQ908 following extra vascular administration

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

  3. Time to maximum plasma concentration of LCQ908

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

  4. The time required for the concentration of the drug to reach half of its original value

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

  5. Apparent volume of distribution of LCQ908 during the terminal elimination phase following extra vascular administration

    Time frame: Serial blood draws conducted on Day 1 (treatment day) followed by additional blood draws on Days 2-10,12, 14, 17, 21 and 29 post dosing

  6. LCQ908 protein binding: unbound area under curve (AUCc) of LCQ908

    Time frame: 10 and 24 hours

  7. LCQ908 protein binding: unbound observed maximum plasma (Cmax) of LCQ908

    Time frame: 10 and 24 hours

  8. LCQ908 protein binding: unbound apparent systemic clearance from plasma (CL/Fu) following extra vascular administration

    Time frame: 10 and 24 hours

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

An Open-label, Parallel-group, Single Dose Study to Assess the Pharmacokinetics of LCQ908 in Patients With Mild, Moderate and Severe Renal Impairment Compared to Age, Gender and Weight-matched Healthy Volunteers.

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Mar 20, 2012
Registry last updated
Dec 19, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.